Role of IL-31 in the pathogenesis of allergic rhinitis
Project/Area Number |
25861563
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Otorhinolaryngology
|
Research Institution | Okayama University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | IL-31 / スギ花粉症 / リンパ球 / IL-33 / IL-2 / 自然リンパ球 / CD127 / IL-5 / ステロイド / IL-37 / Cry j 1 / QOL / VEGF / 線維芽細胞 / IL-4 / クラス2拘束性 / 抗菌ペプチド |
Outline of Final Research Achievements |
66% of peripheral blood mononuclear cells (PBMCs) from patients with Japanese cedar pollinosis produced IL-31 in response to Cry j 1, the major allergen molecule in Japanese cedar pollen. Symptom score and QOL score were significantly higher in patients with positive IL-31 production than those with negative production. IL-31 production by PMBCs were significantly increased following the exposure to IL-2 and IL-33. On the other hand, no induction of IL-31 production was seen in innate lymphoid cells in PBMCs. These results suggest that main IL-31 producing cell in PBMCs was CD4 positive T cells, and the cells are involved in the exacerbation of allergic rhinitis.
|
Report
(4 results)
Research Products
(10 results)
-
-
-
[Journal Article] Cellular Responses to <i>Staphylococcus aureus</i> Alpha-Toxin in Chronic Rhinosinusitis with Nasal Polyps2014
Author(s)
Okano M, Fujiwara T, Kariya S, Higaki T, Haruna T, Matsushita O, Noda Y, Makihara S, Kanai K, Noyama Y, Taniguchi M, Nishizaki K.
-
Journal Title
Allergology International
Volume: 63
Issue: 4
Pages: 563-573
DOI
NAID
ISSN
1323-8930, 1440-1592
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
-
-